The average one-year price target for MariMed (OTCPK:MRMD) has been revised to $0.08 / share. This is a decrease of 51.52% from the prior estimate of $0.17 dated March 25, 2026.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $0.08 to a high of $0.08 / share. The average price target represents a decrease of 59.20% from the latest reported closing price of $0.20 / share.
What is the Fund Sentiment?
There are 4 funds or institutions reporting positions in MariMed. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to MRMD is 0.01%, an increase of 22.36%. Total shares owned by institutions decreased in the last three months by 0.00% to 971K shares.
What are Other Shareholders Doing?
Canton Hathaway holds 645K shares representing 0.16% ownership of the company. No change in the last quarter.
Ransom Advisory holds 322K shares representing 0.08% ownership of the company. No change in the last quarter.
Flagship Wealth Advisors holds 4K shares representing 0.00% ownership of the company. No change in the last quarter.
Game Plan Financial Advisors holds 0K shares representing 0.00% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
